Autopsy report · NCT05641324
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Cause of deathSlow enrollment
“The study was ended due to a lack of recruitment”
Life of this trial
- Registered 2 months before it started.
- Ran for about 5 months before it stopped.
- 4 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Anaveon AG
- Sponsor type
- Industry
- Conditions
- Multiple Myeloma; Relapsed Cancer; Refractory Multiple Myeloma; Adult Disease; Hematologic Diseases
- Interventions
- ANV419; Lenalidomide with low-dose dexamethasone; Daratumumab
- Participants
- 4
- Sites
- 11
- Countries
- Denmark, France, Germany, Spain, Switzerland
Trials that died the same way
- Study of Vascular Function Before vs After Smoking an E-cigarette as Compared to a Normal Cigarette
“due to recruitment reasons the study was prematurely ended” - Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
“The study was stopped due to recruitment difficulties” - The Gene Expression Studies of the Role of Tumor Microenvironments in Tumor Progression
“the study has stopped due to no recruitment” - To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
“the study was early terminated due to lack of recruitment.” - Comparing Palliative Radiotherapy With or Without Carboplatin
“The study was stopped due to insufficient recruitment.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.